The two oligonucleotide-based drugs on the market, that have recently been approved by U.S. FDA, have modified chemical backbone made of phosphorothioates. The therapeutic advantages of the phosphorothioate group and the new types of gene expression-regulation oligonucleotide drugs that it is enabling are detailed in a Review article in iNucleic Acid Therapeutics/i, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available free on the iNucleic ...
Read MoreYou have just read an article categorized health
titled Success of Oligonucleotide Therapeutics Enabled by Modified DNA Backbone.
Written by:
editor - Thursday, November 13, 2014
There are currently no comments for "Success of Oligonucleotide Therapeutics Enabled by Modified DNA Backbone"
Post a Comment